Home » Topics » Regulatory » EMA

EMA
RSS

EC grants orphan status to pralatrexate for cutaneous T-cell lymphoma

June 21, 2010

OBI-1 obtains positive opinion for orphan drug status in Europe

June 18, 2010

EMA approves update to bortezomib label for multiple myeloma

June 17, 2010

COMP recommends orphan drug status for 2B3-101 in glioma

June 16, 2010

EMA's COMP recommends orphan status for DR Cysteamine in cystinosis

June 16, 2010

European Commission extends indication of RoActemra

June 10, 2010

Sunesis receives scientific advice from EMA on voreloxin program

June 3, 2010

EMA considers postapproval commitment fulfilled for Ceplene/IL-2 in AML

June 2, 2010

Wyeth Europa notifies EMA of withdrawal of MAA for Brilence

June 1, 2010

FDA and EMA approve reanalysis of images from phase III RG-1068 trial

May 31, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 24, 2026.
Brain-penetrant NLRP3 inhibitor shows promise in Parkinson’s
BioWorld Science
Researchers from Changchun Genescience Pharmaceuticals Co. Ltd. described the discovery and preclinical profile of an NLRP3 inhibitor with favorable brain...
4D Nucleome opens new wave of gene regulation research, discovery
BioWorld
After a decade of research, the NIH 4D Nucleome program on July 23 delivered a wealth of new insights into how spatial changes in chromatin structure and DNA...
Transcripta Bio raises funding to advance neuro pipeline
BioWorld Science
Transcripta Bio Inc. has raised $24 million since its series A to fund IND-enabling studies across its portfolio and support clinical preparation in its autism...
Daybu readthrough in EU? Zevra’s NPC bid flounders
BioWorld
Zevra Therapeutics Inc. will try to follow in the footsteps of Acadia Pharmaceuticals Inc. with Rett syndrome drug Daybu (trofinetide) by asking the EMA’s...